Aspartic proteinases in disease: A structural perspective

Current Drug Targets

Volumn 3, Issue 2, 2002, Pages 155-173

  Cooper, J B ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; ANGIOTENSIN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; ASPARTIC PROTEINASE; ASPARTIC PROTEINASE INHIBITOR; BETA SECRETASE; BRADYKININ; CARBONYL DERIVATIVE; CATHEPSIN D; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LYSOSOME ENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGOPEPTIDE; PEPSIN A; PLASMEPSIN I; PLASMEPSIN II; PROLACTIN; PROTEINASE; PROTON PUMP INHIBITOR; RENIN; RENIN INHIBITOR; SOMATOMEDIN B RECEPTOR; STATINE DERIVATIVE; STEROID; UNINDEXED DRUG; VIRUS ENZYME;

ALZHEIMER DISEASE; ARTICLE; BREAST CANCER; CANDIDIASIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DESIGN; DRUG METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEN BOND; HYPERTENSION; MALARIA; PEPTIC ULCER; PROTEIN DENATURATION; PROTEIN HYDROLYSIS; PROTEIN STRUCTURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROVIRUS; TISSUE INJURY; VIROGENESIS;

EID: 0036218648     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389450024605382     Document Type: Article

References (77)

1. Enzymes of the renin-angiotensin system and their inhibitors
2. The global impact of HIV/AIDS
3. Targeting the HIV-protease in AIDS therapy: A current clinical perspective
4. Alzheimer's disease: Molecular concepts and therapeutic targets
5. Molecular structure of a fibrillar Alzheimer's Aβ fragment
6. Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor
7. Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors
8. Structural study of the complex between human pepsin and a phosphorus-containing peptidic transition-state analog
9. Anti-human procathepsin D activation peptide antibodies inhibit breast cancer development
10. Mitogenic function of human procathepsin-D - The role of the propeptide
11. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum
12. Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library
13. On the rational design of renin inhibitors: X-ray studies of aspartic proteinases complexed with transition state analogues
14. The active sites of aspartic proteinases
15. X-ray analyses of peptide-inhibitor complexes define the structural basis of specificity for human and mouse renins
16. Computer graphics modelling of human renin
17. Structural plasticity broadens the specificity of an engineered protease
18. Structural comparison of 21 inhibitor complexes of the aspartic proteinase from Endothia parasitica
19. High resolution X-ray analyses of renin inhibitor-aspartic proteinase complexes
20. 1 site
21. Cryoenzymology of penicillopepsin
22. Potent new inhibitors of human renin
23. Renin inhibitors. Design of angiotensin transition state analogues containing statine
24. Highly potent and specific inhibitors of human renin
25. Statine containing dipeptide and tripeptide inhibitors of human renin
26. Fluoroketone inhibitors of hydrolytic enzymes
27. Chemistry of renin inhibitors
28. Highly potent and specific inhibitors of human renin
29. X-ray studies of aspartic proteinase-statine inhibitor complexes
30. Novel renin inhibitors: Synthesis of aminostatine and comparison with statine-containing analogues
31. Renin inhibitors containing the novel amino-acid 3-amino-deoxystatine
32. Synthesis of analogues of the carboxyl proteinase inhibitor pepstatin. Effect of structure on the inhibition of pepsin and renin
33. High resolution X-ray diffraction study of the complex between endothiapepsin and an oligopeptide inhibitor: The analysis of inhibitor binding and description of the rigid body shifts in the enzyme
34. New human renin inhibitors containing an unnatural amino acid, norstatine
35. Human renin: An new class of inhibitors
36. A rational approach to the design of antihypertensives: X-ray studies of complexes between aspartic proteinases and aminoalcohol inhibitors
37. Analyses of ligand binding in five endothiapepsin crystal complexes and their use in the design and evaluation of novel renin inhibitors
38. Phosphinic acid dipeptide analogues: Potent, slow-binding inhibitors of aspartic proteinases
39. Renin inhibitors
40. Design and synthesis of potent and specific renin inhibitors containing difluorostatine, difluorostatone and related analogues
41. Direct observation by X-ray analysis of the tetrahedral "intermediate" of aspartic proteinases
42. Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus chinensis: Implications for a mechanism of action
43. How the molten globule became
44. 2 histidine site
45. New inhibitors of human renin that contain novel Leu-Val replacements
46. X-ray crystallographic analysis of inhibition of endothiapepsin by cyclohexyl renin inhibitors
47. X-ray structures of five renin inhibitors bound to saccharopepsin: Exploration of active-site specificity
48. The design and synthesis of angiotensin converting enzyme inhibitor cilazapril and related bicyclic compounds
49. Renin inhibitors. Design and synthesis of a new class of conformationally restricted analogues of angiotensinogen
50. Synthesis and biological activity of new conformationally restricted analogues of pepstatin
51. Protection groups increase the in vivo stability of a statine-containing renin inhibitor
52. Renin inhibitors. Dipeptide analogues of angiotensinogen incorporating transition-state, nonpeptidic replacements at the scissile bond
53. Renin inhibitors
54. Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 Å resolution
55. X-ray analysis at 2.0 Å resolution of mouse submaxillary renin complexed with a decapeptide inhibitor CH-66, based on the 4-16 fragment of rat angiotensinogen
56. High resolution crystal-structures of recombinant human renin in complex with polyhydroxymonoamide inhibitors
57. Structure-based drug design: The discovery of novel nonpeptide orally active inhibitors of human renin
58. Conserved folding in retroviral proteinases: Crystal structure of synthetic HIV-1 proteinase
59. X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes
60. Renin cleavage of a human-kidney renin substrate analogous to human angiotensinogen that is human renin specific and resistant to cathepsin D
61. Comparative enzymatic studies of human renin acting on pure natural or synthetic substrates
62. Subsite specificity of porcine pepsin
63. Kinetics of the reaction of renin with nine synthetic peptide substrates
64. Characterisation of recombinant human renin - Kinetics, pH-stability and peptidomimetic inhibitor binding
65. Inhibitors of HIV-1 protease: A major success of structure-assisted drug design
66. Cyclic HIV protease inhibitors capable of displacing the active site structural water molecule
67. Structure of a secreted aspartic protease from C. Albicans complexed with a potent inhibitor: Implications for the design of antifungal agents
68. Candida proteases and their inhibition: Prospects for antifungal therapy
69. Molecular-structure of an aspartic proteinase zymogen, porcine pepsinogen, at 1.8 Å resolution
70. Crystal structure of the novel aspartic proteinase zymogen proplasmepsin II from Plasmodium flaciparum
71. Conformational switching in an aspartic proteinase
72. The aspartic proteinase from Saccharomyces cerevisiae folds its own inhibitor into a helix
73. Structural basis for the inhibition of porcine pepsin by Ascaris pepsin inhibitor-3